Objective To investigate the Seretide in the treatment of moderate and severe COPD (Chronic obstructive pulmonary disease) to improve lung function in patients with you, inflammation status and clinical therapeutic effect. Methods 70 cases of patients with severe COPD from December 2015 to December 2016 in our hospital, according to the different treatment methods were divided into two groups, 35 cases in each group, two groups of patients were given conventional treatment, the control group was given the treatment of Theophylline Sustained-release Tablets, on the basis of the observation group patients were given Seretide treatment, observe two groups of patients before and after treatment, lung function, inflammatory factors expression, dyspnea score the changes recorded in patients with clinical efficacy after treatment, and compared. Results After treatment, the pulmonary function indexes such as FEV1, FVC and FEV1/FVC were improved, and the difference between the two groups was statistically significant; the expression levels of inflammatory factors in the treatment of patients before the comparison, no statistically significant; after the treatment, the expression level of serum inflammatory factors in patients with IL-6, CRP and TNF- etc were decreased, the observation group than the control group, the difference was significant after treatment; , dyspnea score of patients were lower than those before treatment, the observation group (1.56+0.32) lower than that of control group (1.98 + 0.42), significant difference; after treatment, the total effective rate was 94.29% higher than 71.43% in the control group, significant difference the adverse reactions of the observation group was 5.71%, which was lower than that of the control group (22.86%), and the difference was significant. Conclusion Given the severe Seretide treatment in patients with COPD, can improve the patient’s lung function, relieve the symptoms of breathing difficulties, inhibit the expression of inflammatory cytokines, significant effect.

moderate and severe COPD lung function inflammatory factors